*Advance our knowledge of the basic immunology of inflammation, autoimmunity, cancer, transplantation and infection and to translate this new knowledge to novel strategies for diagnosis, preventation and therapeutic intervention.
*Foster collaborations and further strengthen interactions among the Penn community of immunologists.
Spotlights on IFI
As pancreatic cancer threat grows, so do strategies
A war on pancreas cancer is underway right here at the Abramson Cancer Center. A story in Sunday’s Philadelphia Inquirer featured the work of Jeffrey Drebin, MD, chair of Surgery and the John Rhea Barton Professor of Surgery, and Robert Vonderheide, MD, the Hanna Wise Professor in Cancer Research in the ACC. Drebin and Vonderheide—both co-leads on Stand up to Cancer Dream Teams—are investigating new targeted therapies, immunotherapies, and more, to better the understand and treat the disease, which is projected to become this country's second-leading cancer killer. "We absolutely need to figure it out," said Vonderheide. "It's a medical emergency." Ongoing studies at the ACC have shed light on tumor biology and shown success with the antimalarial drug hydroxychloroquine. "We're not declaring victory,” Drebin told the Inquirer. “We're declaring progress.”.
FY14 Immunology Catalyst Pilot Grant Awardees
Congratulations to the following Awardees
PI: Aimee Payne, M.D., Ph.D.
"Desmoglein 3 chimeric autoantibody receptor (CAAR)-engineered T cells: a novel strategy for treatment of pemphigus vulgaris"
PI: Sunny Shin, Ph.D.
"Defining Novel Regulators of Inflammasome Activation by Forward Genetics"
PI: Matthew Weitzman, Ph.D.
"The role of cellular chromatin factors in intrinsic antiviral defense"